We use cookies on this site. By browsing our site you agree to our use of cookies. Close this message Find out more

Home > School Seminar - Dr Kyriascos Mitrophanous
More in this section Previous Years

School Seminar - Dr Kyriascos Mitrophanous

Date(s)
13/11/2013 (16:05-17:00)
Description

Dr Kyriacos Mitrophanous
Oxford Biomedica PLC
Oxford

“Gene Therapy for Parkinson Disease and other Neurodegenerative Conditions”

Oxford Biomedica PLC: From Oxford University spin out to one of the leading companies in gene and immunotherapy, this timeline summarises some of our major milestones. - See more at: http://www.oxfordbiomedica.co.uk/history/#sthash.SYWVsA6e.dpuf. OBM has advanced gene therapy products and programmes in the clinic to treat blindness, dementia and cancer.

Kyriacos Mitrophanous obtained his PhD from the University of London where he worked on characterising chemokine receptors which are involved in directing cell movement. He then moved to Oxford University where he was involved in a number of research areas, particularly lentiviral vector development for research and clinical use. He has over 16 years of experience with lentiviruses and the development of clinically relevant lentiviral based vectors and supporting intellectual property (platform technology, production and analytics). Kyriacos is responsible for the research facilities, analytical development and platform development. In addition he heads up the research and development activity to identify and develop new product candidates. He is a named inventor on several patents in the field.

See more at: http://www.oxfordbiomedica.co.uk/team/other-senior-management/12/view/#sthash.biPsWsV9.dpuf

Host - Prof George Dickson

 


   
 
 
 

Comment on this page

Did you find the information you were looking for? Is there a broken link or content that needs updating? Let us know so we can improve the page.

Note: If you need further information or have a question that cannot be satisfied by this page, please call our switchboard on +44 (0)1784 434455.

This window will close when you submit your comment.

Add Your Feedback
Close